-
EBMT 2025 | Prof. Fang Liu: From Predictive Models to Rare Disease Cures—Advancing Pediatric Cord Blood Transplantation
At the 2025 EBMT Annual Meeting, cord blood transplantation (UCBT) emerged as a transformative strategy in the treatment of pediatric hematologic malignancies. Hematopoietic stem cell transplantation (HSCT) remains a life-saving therapy, and UCBT is gaining attention for its unique clinical advantages. During the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation…
-
EBMT 2025 | Prof. Xiaoxia Hu: Focusing on Comprehensive Leukemia Management and Key Findings from the Ruijin Transplant Team
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a cornerstone in the treatment of various hematologic diseases. However, several peri-transplant challenges persist, particularly regarding the optimal timing of transplantation, the role of consolidation therapy, and maintenance strategies. At the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025), the transplant team…
-
EBMT 2025 | Prof. Qifa Liu: Emerging Strategies for GVHD Prevention—Mesenchymal Stem Cells and Fecal Microbiota Transplantation
The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025) was held from March 30 to April 2 in the historic city of Florence, Italy. As one of the most influential global events in the field of hematology, the Annual Meeting gathered over 5,000 experts and scholars from around the…
-
EBMT 2025 | Prof. Erlie Jiang & Dr. Mingyang Wang: Using CBFB-MYH11 Fusion Transcript Ratios to Guide Transplant Timing in Low-Risk AML
Hematopoietic stem cell transplantation (HSCT) remains a curative treatment for numerous hematologic disorders. Despite its life-saving potential, many clinical challenges persist, particularly concerning patient selection, transplant timing, and long-term management. To enhance academic exchange and practical insights in the field of transplantation, Hematology Frontier launched the special feature “Transplantation Pathways Spotlight” during the 51st Annual…
-
EBMT 2025| Prof. He Huang: A Transplant-CAR-T-Nursing Triad Unleashes New Momentum in Hematology
Hematopoietic stem cell transplantation (HSCT) remains a cornerstone therapy for hematologic diseases. However, despite its curative potential, many clinical challenges persist. To promote academic exchange and practical innovation in the field of transplantation, Hematology Frontier launched the “Transplantation Pathways Spotlight” during the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT…
-
Can We Prevent CAR T-Associated Neurotoxicity Without Compromising Efficacy?
At EBMT25, Dr. Janaki Manoja Vinnakota presented compelling data on the role of microglial TAK1 activation in the development of CAR T cell therapy-associated neurotoxicity (ICANS). In her presentation titled…
-
EAU 2025 | Dr. Ashwin Sachdeva: ADT Therapy for mHSPC Upgraded—Combination with Metformin Improves Survival in High-Volume Patients and Reduces Metabolic Syndrome Risk
Currently, ADT remains the cornerstone treatment regimen for mHSPC. However, long-term use of ADT may increase the risk of cardiovascular events. Recently, the data from the STAMPEDE study presented at the European Association of Urology (EAU) Congress showed that the combination of metformin and ADT can extend the overall survival of patients with high tumor…
-
EAU 2025 | Dr. Jeffrey S. Damrauer Shares Insights on Bladder Cancer Classification and Treatment
Bladder cancer is a biologically heterogeneous disease, and its classification plays a critical role in guiding treatment. However, current bladder cancer classification remains based primarily on clinical-pathological features or staging, with molecular subtyping yet to be standardized. At the 2025 European Association of Urology (EAU) Congress, Dr. Jeffrey S. Damrauer from the UNC Lineberger Comprehensive…
Connecting Medical Expertise through Media